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A report of the First Golden Helix Symposium ‘Copy
Number Variation (CNV) and Genomic Alterations in Health
and Disease’, Athens, Greece, 28-29 November 2008.
Since its development in the late 1990s, microarray-based
comparative genomic hybridization (aCGH) has been widely
used to screen for copy-number changes at high resolution
across whole genomes. It has quickly become a reference
method for the diagnosis of patients with severe
developmental defects and has been instrumental in the
discovery of a new abundant source of polymorphism in the
human genome, called DNA copy number variation (CNV).
Here we report some highlights of the First Golden Helix
Symposium, focusing on the latest advances in the rapidly
evolving field of research on CNV.
C CN NV V   i is s   a a   m ma aj jo or r   c ca au us se e   o of f   c ch hr ro om mo os so om ma al l   d di is so or rd de er rs s   i in n
p pa at ti ie en nt ts s
Chromosomal imbalances are a major known cause of
learning disability and developmental defects. A standard
karyotype can only detect chromosomal imbalances (deletions
and duplications) larger than 5 Mb, whereas aCGH is able to
detect cryptic chromosomal imbalances that are not detec-
table by standard cytogenetic analysis. Since the recent imple-
mentation of aCGH in clinical diagnosis, large numbers of
patients have been tested worldwide and genomic copy
number alterations have been detected in around 10-15% of
such patients with apparently normal karyotypes.
Pawel Stankiewicz (Baylor College of Medicine, Houston,
USA) reported a large study in which more than 18,500
patients with mental retardation with or without anatomical
malformations have been screened by aCGH. DNA samples
from patients were analyzed using custom bacterial artificial
chromosome (BAC) arrays until March 2007, when BACs
were replaced by oligonucleotides. Overall, chromosomal
imbalances with clinical significance were identified in 14%
of the patients. This enormous dataset led to the discovery of
several recurrent genomic disorders, in particular, micro-
deletions and microduplications on chromosome 1q21.1 in a
series of individuals with developmental delay and neuro-
psychiatric abnormalities. The 1q21.1 microdeletions found
in the Baylor study can be de novo, or be inherited from a
mildly affected parent, or be inherited from an apparently
unaffected parent. Patients with 1q21.1 microdeletions
present with considerable variability in phenotype, including
mild-to-moderate mental retardation, neuropsychiatric
abnormalities, abnormal head size, dysmorphic features and
congenital anomalies. The potential for reduced penetrance
and variable expressivity in these syndromes raises difficult
questions in the context of genetic counseling for newly
diagnosed cases and particularly for prenatal diagnosis.
aCGH was also used to determine the frequency of genomic
imbalances in neonates with birth defects. Stankiewicz and
colleagues screened 638 neonates and identified a clinically
significant abnormality in 17.1% of them, showing that
chromosomal microarray analysis is a valuable clinical diag-
nostic tool that allows precise and rapid identification of
genomic imbalances and mosaic abnormalities as the cause
of birth defects in neonates.
Joris Veltman (Radboud University Nijmegen Medical
Centre, Nijmegen, The Netherlands) showed that instead of
using aCGH arrays to screen patients with mental retard-
ation, they have chosen single nucleotide polymorphism
(SNP) arrays. In addition to detecting CNV, such SNP arrays
enable the identification of uniparental isodisomies and the
parental inheritance of imbalances. Veltman reported that
since January 2008, the Nijmegen laboratory is using SNP
arrays instead of karyotypes as the primary screening
method for patients with mental retardation. If a chromo-
somal imbalance is identified using the SNP array, parental
karyotyping and/or fluorescence in situ hybridization (FISH)analyses are performed to identify whether it is a balanced
chromosomal rearrangement, knowledge essential for
accurate genetic counseling.
Currently, a number of different platforms are used to screen
for CNV in patients with mental retardation. An initiative
has been proposed to standardize diagnosis by aCGH. John
Crolla (Wessex Regional Genetics Laboratory, Salisbury,
UK) and his colleagues have designed a 44K oligoarray CGH
to provide both genome-wide coverage at baseline resolution
with the probes available and specific interrogation of
known microdeletion and duplication syndromes. Crolla
reported that together with David Ledbetter from Emory
University in Atlanta, Georgia, his team will make publicly
available a new 180K array design covering most of the
known human microdeletion/duplication syndromes with a
higher density, a reduced coverage of cancer genes and an
even probe distribution across the whole genome.
Bert de Vries (Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands) presented his results on the
17q21.31 recurrent microdeletion syndrome. Patients with
the 17q21.31 microdeletion present with a clearly recogni-
zable clinical phenotype of mental retardation, hypotonia
and a characteristic face. de Vries has found that the
deletions encompass the MAPT  (microtubule-associated
protein tau) gene and are associated with a common inver-
sion polymorphism predisposing to the deletion. Joris
Vermeesch (Catholic University, Leuven, Belgium) demon-
strated how CNV can be associated with Mendelian diseases.
Gene deletions can not only be responsible for autosomal
dominant pathologies (for example, by haploinsufficiency)
but also cause autosomal recessive disorders in the presence
of mutations inactivating the second allele. Duplications can
be responsible for monogenic disease by dosage effect when
the gene and its regulatory sequences are duplicated in their
entirety, but intragenic duplications can also lead to
haploinsufficiency and to recessive disorders. Vermeesch
gave the example of partial duplications of the ATRX gene
leading to an absence of ATRX mRNA and protein.
a aC CG GH H   i in n   p pr re en na at ta al l   a an nd d   p pr re ei im mp pl la an nt ta at ti io on n   d di ia ag gn no os si is s   
To date, aCGH has been mostly used in postnatal diagnosis.
Discussing its utility in prenatal diagnosis, one of us (CLC)
presented a study by targeted BAC array of a series of 49
fetuses with multiple anatomical malformations and normal
karyotype. Most of the known recurrent microdeletion
syndromes, all 41 human subtelomeric chromosome regions,
and 201 additional selected loci representing each chromo-
some arm were spotted on the array. All fetuses presented
with at least three major malformations that led to a
medically terminated pregnancy. In four cases, de novo
genomic imbalances clearly underlying the pathological
phenotype were identified. In one, the relationship between
genotype and phenotype was unclear, as a subtelomeric 6q
deletion was detected in a healthy mother and in her two
fetuses bearing multiple malformations. The detection of
causative chromosomal imbalances in 10% of these fetuses
suggested the desirability of genome-wide screening by
aCGH even when standard chromosome analysis is normal,
and confirmed that aCGH will have a major impact on
prenatal diagnosis.
However, aCGH results should be applied with extreme
caution in prenatal diagnosis because of the possible detec-
tion of CNV with uncertain clinical significance, as indicated
by recent work from elsewhere. Targeted arrays may be pre-
ferred over genome-wide arrays in prenatal diagnosis, to
give better coverage of the targeted regions, to reduce the
number of genes identified for which termination would be
ethically questionable (for example, BRCA, AZF), and to reduce
the number of regions of uncertain clinical significance.
Genome-wide CNV screening in single cells is of special
importance for a variety of applications in basic research and
clinical diagnostics. Prerequisites are technologies for
capturing single cells, unbiased single-cell whole-genome
amplification protocols, and an appropriate array platform
for evaluating the amplification products. The maximal
achievable resolution is a matter of debate. Jochen Geigl
(Medical University, Graz, Austria) together with Michael
Speicher has previously shown that when the amplification
product is hybridized to a whole-genome tiling path BAC
array, a resolution of 6-8 Mb is achievable. He described
how high-resolution oligo-arrays and a new evaluation
algorithm especially designed for the identification of small
CNVs in noisy ratio profiles had led to improved resolution,
with the identification of CNVs as small as 500 kb in cell
pools (5 or 10 cells) and 2.6-3.0 Mb in single cells. Geigl
described how the procedures are also suitable for polar
body analyses in the context of prenatal genetic screening as
they reliably allow the identification of aneuploidy patterns,
the mode of chromosome segregation and segmental
aneuploidies. The approach can also be applied to identify
the amplification products of microdissected single chromo-
somes. Geigl reported that using this approach, they had
narrowed down the breakpoint in a patient with a balanced
de novo translocation involving chromosomes 7 and 13 to
base-pair level.
P Po op pu ul la at ti io on n   g ge en no om mi ic cs s
Until recently, genome-wide interrogation of CNV was not
easily applicable to population-based studies. One of us (RR)
presented preliminary results from the construction of a new
high-resolution CNV map by the Genome Structural
Variation (GSV) consortium. GSV consortium members have
carried out aCGH - using a set of 20 microarrays covering
the whole human genome with 42 million oligonucleotides -
on 40 individuals of African or European ancestry. They
have discovered 11,700 CNVs of more than 500 bp in size
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possible to accurately identify functional sequences that are
variable in copy number, and provide new insights into
mechanisms generating chromosomal rearrangements. New
whole-genome CNV genotyping platforms based on this
high-resolution map will become available within the next
few months and allow more comprehensive case-control
association testing with CNV.
Manolis Dermitzakis (Wellcome Trust Sanger Institute,
Hinxton, UK) has worked for several years on defining the
impact of nucleotide and copy number variation on gene-
expression phenotypes. He gave an update on a new
association survey currently in progress, comparing nucleo-
tide variations and gene transcription levels in individuals
from the HapMap project. By using cell-line samples from
different sources, Dermitzakis and his colleagues have been
able to accurately reproduce previously published data on
the impact of nucleotide variants on gene transcription
levels using SNP data from the phase 1 HapMap project. The
new study will soon be extended to the high-resolution CNV
map under construction by the GSV consortium and will
provide new insights into the link between genetic variation
and expression phenotypes.
In his keynote lecture, Stylianos Antonarakis (University of
Geneva Medical School, Switzerland) reminded the audience
that the concept of CNV was originally described more than
70 years ago in Drosophila. Reviewing his work on the
identification of cis- and trans-regulatory elements in the
human genome, focusing on chromosome 21, he showed
how these data illustrate the new challenges faced by
researchers in human genetics - to better understand the
relationship between genetic variation and phenotypic
diversity. The human genome can no longer be considered as
a simple succession of linear DNA molecules carrying gene-
coding information but should also be viewed as a three-
dimensional regulatory network. Original and innovative
strategies will be required in the future to decode all the
genetic information that is currently released in extensive
catalogs of single-nucleotide and copy number variation.
The participants at the first Golden Helix symposium
enjoyed hearing about new and unpublished work and
taking part in lively and informative discussions with the
speakers. We look forward to the 2009 meeting, which will
be on Stem Cell Biology.
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